Logo image of SXTP

60 DEGREES PHARMA INC (SXTP) Stock Price, Quote, News and Overview

NASDAQ:SXTP - Nasdaq - US83006G4010 - Common Stock - Currency: USD

2.28  -0.2 (-8.06%)

SXTP Quote, Performance and Key Statistics

60 DEGREES PHARMA INC

NASDAQ:SXTP (5/2/2025, 4:12:28 PM)

2.28

-0.2 (-8.06%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High35.99
52 Week Low1.41
Market Cap3.35M
Shares1.47M
Float1.41M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO07-12 2023-07-12


SXTP short term performance overview.The bars show the price performance of SXTP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20

SXTP long term performance overview.The bars show the price performance of SXTP in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of SXTP is 2.28 USD. In the past month the price increased by 31.91%. In the past year, price decreased by -80.32%.

60 DEGREES PHARMA INC / SXTP Daily stock chart

SXTP Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 59.86 780.78B
JNJ JOHNSON & JOHNSON 15.53 376.23B
NVO NOVO-NORDISK A/S-SPONS ADR 20.01 307.32B
NVS NOVARTIS AG-SPONSORED ADR 13.75 225.73B
AZN ASTRAZENECA PLC-SPONS ADR 19.47 224.59B
MRK MERCK & CO. INC. 10.68 209.31B
PFE PFIZER INC 7.54 137.25B
SNY SANOFI-ADR 14.36 135.72B
BMY BRISTOL-MYERS SQUIBB CO 6.89 102.91B
GSK GSK PLC-SPON ADR 7.09 79.05B
ZTS ZOETIS INC 26.59 70.23B
HLN HALEON PLC-ADR 21.84 48.28B

About SXTP

Company Profile

SXTP logo image 60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 3 full-time employees. The company went IPO on 2023-07-12. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

Company Info

60 DEGREES PHARMA INC

1025 Connecticut Avenue Nw, Suite 1000

WASHINGTON WASHINGTON DC US

Employees: 3

Company Website: https://60degreespharma.com/

Investor Relations: https://investors.60degreespharma.com/

Phone: 12023275422

60 DEGREES PHARMA INC / SXTP FAQ

What is the stock price of 60 DEGREES PHARMA INC today?

The current stock price of SXTP is 2.28 USD. The price decreased by -8.06% in the last trading session.


What is the ticker symbol for 60 DEGREES PHARMA INC stock?

The exchange symbol of 60 DEGREES PHARMA INC is SXTP and it is listed on the Nasdaq exchange.


On which exchange is SXTP stock listed?

SXTP stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for 60 DEGREES PHARMA INC stock?

8 analysts have analysed SXTP and the average price target is 5.92 USD. This implies a price increase of 159.47% is expected in the next year compared to the current price of 2.28. Check the 60 DEGREES PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is 60 DEGREES PHARMA INC worth?

60 DEGREES PHARMA INC (SXTP) has a market capitalization of 3.35M USD. This makes SXTP a Nano Cap stock.


How many employees does 60 DEGREES PHARMA INC have?

60 DEGREES PHARMA INC (SXTP) currently has 3 employees.


What are the support and resistance levels for 60 DEGREES PHARMA INC (SXTP) stock?

60 DEGREES PHARMA INC (SXTP) has a support level at 2.06 and a resistance level at 2.82. Check the full technical report for a detailed analysis of SXTP support and resistance levels.


Is 60 DEGREES PHARMA INC (SXTP) expected to grow?

The Revenue of 60 DEGREES PHARMA INC (SXTP) is expected to grow by 109.78% in the next year. Check the estimates tab for more information on the SXTP EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy 60 DEGREES PHARMA INC (SXTP) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does 60 DEGREES PHARMA INC (SXTP) stock pay dividends?

SXTP does not pay a dividend.


What is the Price/Earnings (PE) ratio of 60 DEGREES PHARMA INC (SXTP)?

60 DEGREES PHARMA INC (SXTP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-39.64).


What is the Short Interest ratio of 60 DEGREES PHARMA INC (SXTP) stock?

The outstanding short interest for 60 DEGREES PHARMA INC (SXTP) is 30.26% of its float. Check the ownership tab for more information on the SXTP short interest.


SXTP Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to SXTP. When comparing the yearly performance of all stocks, SXTP is a bad performer in the overall market: 95.1% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SXTP Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to SXTP. Both the profitability and financial health of SXTP have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SXTP Financial Highlights

Over the last trailing twelve months SXTP reported a non-GAAP Earnings per Share(EPS) of -39.64. The EPS decreased by -801.61% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -146.38%
ROE -208.9%
Debt/Equity 0.04
Chartmill High Growth Momentum
EPS Q2Q%-228.7%
Sales Q2Q%440.86%
EPS 1Y (TTM)-801.61%
Revenue 1Y (TTM)168.55%

SXTP Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to SXTP. The Buy consensus is the average rating of analysts ratings from 8 analysts.

For the next year, analysts expect an EPS growth of 90.39% and a revenue growth 109.78% for SXTP


Ownership
Inst Owners2.09%
Ins Owners3.15%
Short Float %30.26%
Short Ratio0.21
Analysts
Analysts80
Price Target5.92 (159.65%)
EPS Next Y90.39%
Revenue Next Year109.78%